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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S281expansion was reliably achieved when artiﬁcial APCs were
used. In contrast, when donor PBMCs (without artiﬁcial
APCs) were used as the source of APCs, 10-100 fold fewer
Tregs were obtained. Regardless of protocol, pTregs suc-
cessfully prevented the proliferation of bead (CD2CD3CD28)
stimulated self PBMCs with up to 50% suppression at a 1:32
ratio of Tregs:PBMCs.
Contamination of CD8+ T cells was observed despite our ef-
forts to gate out CD8 cells during sorting. Re-sorting of the
Treg cultures early (day 14-21 post isolation) successfully
eliminated the CD8s. Re-sorting inherently caused a signiﬁ-
cant loss of Tregs, leading to a longer culture period. Because
Treg burnout was of concern, we assessed the function and
phenotype of cells maintained in cultures >50 days and
observed that Tregs with early high FoxP3 expression
maintained function and phenotype.
Finally, demonstration of ﬁtness of cryopreserved pTregs is
necessary for clinical application. Our preliminary studies
show that Tregs can be re-cultured and re-expanded without
loss of suppression or phenotype. In summary, we have
successfully established several protocols for Treg expansion
in the Cynomolgus macaque that can be used in pre-clinical
studies of transplant tolerance induction.400
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The impact of early donor cell chimerism on outcomes of
reduced-intensity conditioning SCT inmyeloid disorders is ill
deﬁned. To explore the impact of measuring busulfan phar-
macokinetics (Bu PK) in conditioning regimens on early
donor chimerism, we undertook a retrospective analysis of
patients with myeloid disorders who received four days of
ﬂudarabine and busulfanwith orwithoutmeasuring Bu PK at
our center in the last 10 years.
Methods: Chimerism assay was performed using a quanti-
tative ﬂuorescence-based short tandem repeatepolymerase
chain reaction (STR-PCR) with capillary electrophoresis for
PCR product resolution.
Results: Thirty patients were identiﬁed and included in the
study. All patients received ﬂudarabine (40 mg/m2/day x 4
doses), busulfan (3.2mg/kg/dose IV x 4 doses). Of these thirty
patients, 7 had Bu PK measured. There were 21 male and 9
female patients with a median age of 62 years (range
48e72yrs). Median time to follow up was 13.3 months.
Disease risk was considered advanced in 17 patients, inter-
mediate in 3 and early in 10. All patients in the Bu PK group
had advanced disease except one had early disease.
Regarding cytogenetics, all patients in the Bu PK group had
high or intermediate risk cytogenetics. Median blast number
at time of SCT was 5%. Stem cell source included peripheral
blood in all patients.
There were no primary graft failures. Total Donor cell
Chimerism analysis in the Bu PK group showed 100% donor
at both time points (days 30,100) in all patients except in one
who relapsed at day 30 (85.7%). While in the non-PK grouponly 7 out of 23 (30%) patients had complete chimerism at
day 30 and day 100. Complete donor chimerism at day 100 in
the non-PK group was 47.8% compared to 85.7% in the PK
(p¼0.18). Ten out of 23 patients (43.5%) in the non-PK group
had decreasing donor chimerism by day 100, while in the PK
group only one patient (14%) who relapsed had decreasing
donor chimerism by day 100 with an odds ratio of 0.241 (95%
Conﬁdence Interval¼0.025-2.357; p-value¼0.22). None
developed sinusoidal obstructive syndrome.
Conclusion: In this small cohort from a single center, we
found that patients with myeloid disorders who received
ﬂudarabine busulfan for 4 days incorporating Bu PK had a
trend for higher rates of early complete donor chimerism
and less decreasing donor chimerism by day100 despite
having intermediate or high risk disease at time of SCT.
Longer follow up is needed for our patients to see if there
is effect on relapse or survival but previous studies have
showed that low or decreasing donor chimerism early after
SCT is an independent risk factor for relapse and impaired
survival. This is especially important in myeloid disorders.
Bu PK may help target better level for inducing early total
donor chimerism and donor chimerism may identify high-
risk patient cohorts who may beneﬁt from additional
therapeutic interventions.401
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The female donor/male recipient combination increases the
risks of graft-versus-host disease (GVHD) and non-relapse
mortality (NRM) after allogeneic stem cell transplantation
(allo-SCT). To explore the impact of Female matched related
donor (F-MRD) versus male matched unrelated donor
(M-MUD) on outcome of peripheral blood allo-SCT in male
recipients, we undertook a single center retrospective anal-
ysis of male adult patients transplanted at our center in the
last 10 years. We excluded patients who received donor
lymphocyte infusion post SCT.
Methods: Disease-free survival (DFS) and OSwere calculated
using the Kaplan-Meier estimate. Cumulative incidences (CI)
were used for relapse (REL) and GVHD in a competing risks
setting, NRM being a competing event for REL, and death for
GVHD.
Results: Fifty-six patients were identiﬁed and included in
this analysis. The median age at transplant was 57 years (19-
73). Diseases were AML (n¼21), ALL (n¼7), NHL (n¼9),
Hodgkin’s disease (n¼1), myeloma (n¼5), MDS (n¼11), CLL
(n¼1), and CML (n¼1). Conditioning regimens were mye-
loablative (MAC) (n¼35), reduced toxicity ablative (n¼17) or
non myelablative (n¼4). Donors were F-MRD (n¼24) or
M-MUD (n¼32). Source of stem cells was peripheral blood in
all patients. GVHD prophylaxis consisted of tacrolimus and
methotrexate in MRD and tacrolimus, methotrexate and
anti-thymocyte globulin in MUD. Of the female donors, 63%
had previous pregnancies before donation, 8% had no preg-
nancies and 29% were unknown. Mean age of female donors
was 48 while the mean age for male donors was 35.
